Bio & Insurance Information

Dr. Catherine Park is a radiation oncologist in San Francisco, California. She received her medical diploma from David Geffen School of Medicine at UCLA in 1995. After getting her medical degree, she did an internship at Beth Israel Hospital, between 1995 and 1996. Dr. Park completed her medical education with a residency in radiation oncology at Joint Center for radiation therapy, and a fellowship in research at Lawrence Berkeley National Laboratory, between 1998 and 1999. She was an Assistant Clinical Professor in radiation oncology at UCSF between 2000 and 2005, then, she was an Assistant Professor in residence in radiation oncology at UCSF between 2005 and 2014. She was also a visiting scientist in the division of life sciences at Lawrence Berkeley National Laboratory, between 2000 and 2006. Since 2014 until the present time she is a professor of radiation oncology at UCSF. She works at UCSF Medical Center and has published 7 articles in collaboration with other doctors.



Education & Training

David Geffen School of Medicine at UCLA

Medical School

Beth Israel Deaconess Medical Center

Internship

Joint Center for Radiation Therapy

Residency

Lawrence Berkeley National Laboratory

Fellowship

Board Certifications

American Board of Radiology - Radiation Oncology

Hospitals & Clinics

Advocate Good Samaritan Hospital

Languages: English/Spanish

(630) 275-5900

3815 Highland Ave

Downers Grove, Illinois 60515

Read More

Rush University Cancer Center

Languages: English/Spanish

(312) 942-5904

1725 W. Harrison Street, Chicago, IL

Chicago, Illinois 60612

Read More

UCSF Medical Center

Languages: English/Spanish

(415) 353-1037

505 Parnassus Ave

San Francisco, California 94143

Read More

Publications

Dr. Catherine Park has contributed to 3 publications.

Sentinel Lymph Node Mapping in Post-Mastectomy Chest Wall Recurrences: Influence on Radiation Treatment Fields and Outcome.

Johnson, J.,Esserman, L.,Ewing, C.,Alvarado, M.,Park, C.,Fowble, B.; Ann. Surg. Oncol.. 2015 Dec 31.

See more >>

Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin.

Campbell, M. R.,Zhang, H.,Ziaee, S.,Ruiz-Saenz, A.,Gulizia, N.,Oeffinger, J.,Amin, D. N.,Ahuja, D.,Moasser, M. M.,Park, C. C.; Breast Cancer Res. Treat.. 2016 Feb 11.

See more >>

Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors.

Lin, C. H.,Pelissier, F. A.,Zhang, H.,Lakins, J.,Weaver, V. M.,Park, C.,LaBarge, M. A.; Mol. Biol. Cell. 2015 Sep 05.

See more >>